Prof Maciej Wiznerowicz
- Professor of Medicine
- Professor
- International Institute for Molecular Oncology in Poznan
- Poland
Title :
Abstract :
Biography:
Dr Wiznerowicz received his M.D. (1997) and Ph.D. (1998) degrees from the Poznan University of Medical Sciences. Next, he pursued his career at the University of Geneva (2000-2004) and École Politechnique Fédérale de Lausanne (EPFL) in Switzerland (2004-2006), followed by Merck Research Laboratories in Boston, USA (2006-2009). In 2010, Dr Wiznerowicz was awarded with prestigious Welcome grant from the Foundation for Polish Science to 2009 and came back to native Poland with the goal to study molecular mechanisms in stem cells and cancer in collaboration with the MD Anderson Cancer Center. In the same year, he has included GPCC into The Cancer Genome Atlas (TCGA) Program, collaborative effort between National Cancer Institute, the National Human Genome Research Institute and leading oncology hospitals in the world. The major goal of this project is comprehensive molecular analysis of human tumours in order to identify novel molecular mechanisms involved in carcinogenesis and potential new targets for drug discovery. In 2015, together with leading oncologists in Poland, Dr Wiznerowicz founded the International Institute for Molecular Oncology, non-profit research organization for translational cancer research (iimo.pl). The mission of IIMO is to carry out scientific and industrial studies in oncology using the state-of-the-art ICT solutions and computational science to develop and implement innovative methods for prevention, diagnosis and treatment of cancer. The Institute has already received a contract from NCI/NIH to integrate of cancer genomics with the proteomic analyses of various tumour types within the Clinical Proteomic Tumor Analysis Consortium (CPTAC). Dr Wiznerowicz works on the TCGA PanCancer Atlas analyses and leads an international team of computational biologists, statisticians, and clinicians, focused on comprehensive analyses of selected cancer features across over 30 tumour types using TCGA molecular data from various genomic and proteomic platforms.